FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921879437> ?p ?o ?g. }

• W2921879437 endingPage "633" @default.
• W2921879437 startingPage "633" @default.
• W2921879437 abstract "<h3>Importance</h3> Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers. Another effective way of reducing HCC risk needs to be developed. Aspirin may prevent cancer development, but clinical evidence in patients with HBV-related HCC remains limited. <h3>Objective</h3> To investigate the association of daily aspirin therapy with HBV-related HCC risk. <h3>Design, Setting, and Participants</h3> In this Taiwan nationwide cohort study, we screened 204 507 patients with chronic hepatitis B for the period January 1, 1997, to December 31, 2012. After excluding patients with confounding conditions, 2123 patients who continuously received daily aspirin for 90 or more days (treated group) were randomly matched 1:4 with 8492 patients who had never received antiplatelet therapy (untreated group) by means of propensity scores, consisting of the follow-up index date, baseline characteristics, and potentially chemopreventive drug use during follow-up. Data were analyzed from August 1 to November 30, 2018. <h3>Exposures</h3> Daily aspirin therapy during the study period. <h3>Main Outcomes and Measures</h3> Both cumulative incidence of and hazard ratios (HRs) for HCC development were analyzed after adjusting patient mortality as a competing risk event. <h3>Results</h3> Of the 10 615 patients included in the analysis, 7690 (72.4%) were men; mean (SD) age was 58.8 (11.8) years. The cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in 5 years (5.20%; 95% CI, 4.11%-6.29% vs 7.87%; 95% CI, 7.15%-8.60%;<i>P</i> < .001). In the multivariable regression analysis, aspirin therapy was independently associated with a reduced HCC risk (HR, 0.71; 95% CI, 0.58-0.86;<i>P</i> < .001). Sensitivity subgroup analyses also verified this association (all HRs <1.0). In addition, older age (HR, 1.01 per year; 95% CI, 1.00-1.02), male sex (HR, 1.75; 95% CI, 1.43-2.14), and cirrhosis (HR, 2.89; 95% CI, 2.45-3.40) were independently associated with an increased HCC risk, but nucleos(t)ide analogue (HR, 0.54; 95% CI, 0.41-0.71) or statin (HR, 0.62; 95% CI, 0.42-0.90) use was correlated with a decreased HCC risk. <h3>Conclusions and Relevance</h3> Daily aspirin therapy may be associated with a reduced risk of HBV-related HCC." @default.
• W2921879437 created "2019-03-22" @default.
• W2921879437 creator A5002888892 @default.
• W2921879437 creator A5011571171 @default.
• W2921879437 creator A5014703182 @default.
• W2921879437 creator A5024370956 @default.
• W2921879437 creator A5034319011 @default.
• W2921879437 creator A5048137173 @default.
• W2921879437 creator A5075844176 @default.
• W2921879437 date "2019-05-01" @default.
• W2921879437 modified "2023-10-15" @default.
• W2921879437 title "Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B" @default.
• W2921879437 cites W1985070288 @default.
• W2921879437 cites W1987837071 @default.
• W2921879437 cites W2020775220 @default.
• W2921879437 cites W2042265219 @default.
• W2921879437 cites W2042921846 @default.
• W2921879437 cites W2043632765 @default.
• W2921879437 cites W2051445975 @default.
• W2921879437 cites W2058989785 @default.
• W2921879437 cites W2083557491 @default.
• W2921879437 cites W2087556175 @default.
• W2921879437 cites W2087645894 @default.
• W2921879437 cites W2089571778 @default.
• W2921879437 cites W2094051823 @default.
• W2921879437 cites W2098964407 @default.
• W2921879437 cites W2100012557 @default.
• W2921879437 cites W2105051117 @default.
• W2921879437 cites W2107601538 @default.
• W2921879437 cites W2111175587 @default.
• W2921879437 cites W2112244490 @default.
• W2921879437 cites W2116836111 @default.
• W2921879437 cites W2123060376 @default.
• W2921879437 cites W2138029572 @default.
• W2921879437 cites W2147064398 @default.
• W2921879437 cites W2150912899 @default.
• W2921879437 cites W2154239359 @default.
• W2921879437 cites W2154373299 @default.
• W2921879437 cites W2158373383 @default.
• W2921879437 cites W2173698250 @default.
• W2921879437 cites W2174723704 @default.
• W2921879437 cites W2180289658 @default.
• W2921879437 cites W2252361481 @default.
• W2921879437 cites W2331422116 @default.
• W2921879437 cites W2555186588 @default.
• W2921879437 cites W2605785536 @default.
• W2921879437 cites W2614406656 @default.
• W2921879437 cites W2625119531 @default.
• W2921879437 cites W2917837889 @default.
• W2921879437 cites W4211026375 @default.
• W2921879437 cites W4239728164 @default.
• W2921879437 cites W4240852241 @default.
• W2921879437 cites W4245403358 @default.
• W2921879437 cites W4250963925 @default.
• W2921879437 cites W4254607934 @default.
• W2921879437 cites W4256121557 @default.
• W2921879437 doi "https://doi.org/10.1001/jamainternmed.2018.8342" @default.
• W2921879437 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6503573" @default.
• W2921879437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30882847" @default.
• W2921879437 hasPublicationYear "2019" @default.
• W2921879437 type Work @default.
• W2921879437 sameAs 2921879437 @default.
• W2921879437 citedByCount "111" @default.
• W2921879437 countsByYear W29218794372019 @default.
• W2921879437 countsByYear W29218794372020 @default.
• W2921879437 countsByYear W29218794372021 @default.
• W2921879437 countsByYear W29218794372022 @default.
• W2921879437 countsByYear W29218794372023 @default.
• W2921879437 crossrefType "journal-article" @default.
• W2921879437 hasAuthorship W2921879437A5002888892 @default.
• W2921879437 hasAuthorship W2921879437A5011571171 @default.
• W2921879437 hasAuthorship W2921879437A5014703182 @default.
• W2921879437 hasAuthorship W2921879437A5024370956 @default.
• W2921879437 hasAuthorship W2921879437A5034319011 @default.
• W2921879437 hasAuthorship W2921879437A5048137173 @default.
• W2921879437 hasAuthorship W2921879437A5075844176 @default.
• W2921879437 hasBestOaLocation W29218794371 @default.
• W2921879437 hasConcept C120665830 @default.
• W2921879437 hasConcept C121332964 @default.
• W2921879437 hasConcept C126322002 @default.
• W2921879437 hasConcept C167135981 @default.
• W2921879437 hasConcept C201903717 @default.
• W2921879437 hasConcept C203014093 @default.
• W2921879437 hasConcept C207103383 @default.
• W2921879437 hasConcept C2522874641 @default.
• W2921879437 hasConcept C2777382497 @default.
• W2921879437 hasConcept C2777628954 @default.
• W2921879437 hasConcept C2778019345 @default.
• W2921879437 hasConcept C2780593183 @default.
• W2921879437 hasConcept C44249647 @default.
• W2921879437 hasConcept C61511704 @default.
• W2921879437 hasConcept C71924100 @default.
• W2921879437 hasConcept C72563966 @default.
• W2921879437 hasConcept C88879693 @default.
• W2921879437 hasConceptScore W2921879437C120665830 @default.
• W2921879437 hasConceptScore W2921879437C121332964 @default.
• W2921879437 hasConceptScore W2921879437C126322002 @default.
• W2921879437 hasConceptScore W2921879437C167135981 @default.

• next